Bumetanide is a sulfamyl diuretic used to treat edema in congestive heart failure, hepatic and renal disease, and nephrotic syndrome. A medication used to treat swelling from water retention.
- Mechanism
- Curator reviewed
Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis.
- Primary indication
- For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.Curator reviewed · 3 structured indications
- Formula / weight
- C17H20N2O5S · 364.416 g/mol (avg)
- First approval
- Canada, 2022 · United States, 1983
- Code names
- CS 380 · RO 10-6338
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
MAEIEVLCKWDQJH-UHFFFAOYSA-NSMILESCCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=OWhat you can answer from here — as of September 23, 2026
5Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
6TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Bumetanide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account